CASI Pharmaceuticals, Inc. (NASDAQ:CASI) will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website www.casipharmaceuticals.com
Earnings Expectation
CASI Pharmaceuticals, Inc. is expected to report third quarter earnings results, before market open, on Monday 9th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.05 per share from revenue of $ 3.44 million. Looking ahead, the full year loss are expected at $ 0.25 per share on the revenues of $ 12.24 million.
CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The companys product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprises ZEVALIN, an ibritumomab tiuxetan injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-Hodgkins lymphoma, as well as for the treatment of patients with previously untreated follicular non-Hodgkins lymphoma; and MARQIBO, a microtubule inhibitor to treat adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
